The Journal of Urology · 2000 · 358 citations · 25 references
MedicineOncologyPharmacologyCancer PharmacologyMetastasisMolecular OncologyGenitourinary Cancer PharmacotherapyMalignant NeoplasmsOncology PharmacologyPharmacodynamics Of Anticancer AgentsProstate CancerCyclooxygenase InhibitorsCyclooxygenase IsoformsCyclooxygenase-2 PathwayFactor Viii ActivationImmunohistochemical MarkersImmunohistochemical StainingIn Vivo Efficacy TestingTumor Suppression Mechanisms
PURPOSE: Cyclooxygenase (COX)-2, an inducible enzyme which catalyzes the formation of prostaglandins from arachidonic acid, is expressed in prostate cancer specimens and cell lines. To evaluate the in vivo efficacy of a COX-2 inhibitor in prostate cancer, NS398 was administered to mice inoculated with the PC-3 human prostate cancer cell line. MATERIALS AND METHODS: A total of 28 male nude mice were inoculated subcutaneously with 1 million PC-3 cells. Tumors were palpable in all 28 animals 1 week after inoculation and mice were randomized to receive either vehicle (control) or NS398, 3 mg./kg. body weight, intraperitoneally three times weekly for 9 weeks. Tumors were measured at weekly intervals. After a 10-week experimental period, mice were euthanized and tumors were immuno- histochemically assayed for proliferation (PCNA), apoptosis (TUNEL) and microvessel density (MVD) (Factor-VIII-related antigen). Tumor VEGF content was assayed by Western blotting. RESULTS: NS398 induced a sustained inhibition of PC-3 tumor cell growth and a regression of existing tumors. Average tumor surface area from control mice was 285 mm.2 as compared with 22 mm.2 from treated mice (93% inhibition, p <0.001). Immunohistochemical analysis revealed that NS398 had no effect on proliferation (PCNA), but induced apoptosis (TUNEL) and decreased MVD (angiogenesis). VEGF expression was also significantly down regulated in the NS398-treated tumors. CONCLUSIONS: These results demonstrate that a selective COX-2 inhibitor suppresses PC-3 cell tumor growth in vivo. Tumor growth suppression is achieved by a combination of direct induction of tumor cell apoptosis and down regulation of tumor VEGF with decreased angiogenesis
25
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al. · Cell · 1997 · 4.5K citations · Full text
Medicine, Oncology, Pharmacology +11
Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells
Masahiko Tsujii, Sunao Kawano, Shingo Tsuji et al. · Cell · 1998 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Dean A. Kujubu, Bradley S. Fletcher, Brian Varnum et al. · Journal of Biological Chemistry · 1991 · 1.8K citations · Full text
T. Tong, S. Bolden, Phyllis A. Wingo · CA A Cancer Journal for Clinicians · 1996 · 1.8K citations · Full text
Medicine, Biostatistics, Oncology +17